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Hepatitis B (HVB) is one of the most common infectious diseases in the 
world. Its wide geographical distribution is a health problem, especially on 
the African continent, with prevalence rate of 6.1% in the adult population. 
Current treatment requires prolonged therapy (most cases for the rest of life) 
with the aim of stopping viral replication, maintaining immunological stability, 
preventing progression of liver disease and the most feared complications 
such as cirrhosis and hepatic cancer.
There are multiple references for ozone therapy as an alternative in the 
treatment of Hepatitis B, because of the known and demonstrated 
antimicrobial and immune modulatory properties. With these promises, we 
performed the present clinical study that included 28 patients with positive 
diagnosis of chronic Hepatitis B, surface antigen (HVBs Ag) positive, 
antibodies against surface antigen (HVBs) negative, viral load (HVB DNA) 
and transaminases elevated. These patients with 1 year of evolution and 
antiviral treatment were treated with major autohemotherapy with protocol of 
15 sessions and maintenance every 15 days with an ozone concentration of 
50 µg/ml, with an initial dose of 4,000 µg up to 12,000 µg. 
We indicate Ag HVBs, Ac HVBs, HVB Viral Loading and transaminases 
before starting treatment, at 15 days of completion and quarterly until the 
year. The results showed negative of HBsAb tests from, a positive anti-
HBsAb test (Hepatitis B surface antibody), significant decrease of viral load 
to undetectable values and normal values of the transaminases 
demonstrating the functional recovery of the disease, associated with 
favorable immunological response, providing a better quality of patients' 
lives. 
Keywords:  Hepatitis B, Transaminases, Ozone therapy, Major Autohemotherapy, Surface 
antigen, Surface Antigen Antibody.

Introduction 
Hepatitis B is a liver infectious disease caused by Hepatitis B virus (HBV), 
which belongs to the family Hepadnaviridae (hepatotropic DNA virus) and is 
characterized by hepatocellular necrosis and inflammation [1].
The development of serological tests for the different antigens and their 
respective antibodies has revealed the worldwide distribution of HBV, with 
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population, 2,000 million people have been infected by HBV, and of these, 
about 350-400 million are chronic carriers. By 2015, 257 million people were 
living with chronic infection, mainly affecting the African and Western Pacific 
Region. Most of the deaths were due to chronic liver disease (720,000 
cirrhosis) and primary liver cancer (470,000 hepatocellular carcinoma 
deaths) [2,3,4,5].
There are now many reasons to approach the treatment of chronic hepatitis 
from an etiological point of view, on the evidence that the evolution depends 
on causative agent, replicative state, activity degree and the disease stage.
The treatment of chronic liver injury by B virus is based on the 
etiopathogenic mechanisms that produce it, on the demonstration of the non-
cytopathic effect of HBV and, therefore, on its origin due to an immune 
specific reaction of the host mediated by activated cytotoxic T 
lymphocytes_[6].
With the development of medicine, antiviral treatment has improved the 
prognosis of the disease and the quality of life of those affected. However, 
there are also other natural treatments that perfectly complement the 
pharmacological ones. Ozone therapy has become a useful therapy for the 
treatment of many pathological processes such as hepatitis, probably due to 
the viral inactivation by generated endoperoxides, as well as stimulation of 
cytokines release. Medical ozone has antibacterial, antifungal and antivirus 
effect. Ozone through its active metabolite is able to modulate the 
immunological system in order to eliminate the virus [7,8].
Several scientific studies have postulated Ozone as an excellent modulator 
of the immune system and its contribution to the recovery of viral diseases 
such as hepatitis B, particularly by the effects on monocytes and T 
lymphocytes, in addition to which the production of accompanied cytokines is 
stimulated of an improvement of the oxygenation and the metabolism. 
The action of ozone on the immune cell is compared with the effect caused 
by mitogens. In cytokinetic induction of immunocompetent cells, CD4 + T 
lymphocytes (helpers) activated by macrophages produce cytokines that 
initiate intercellular communication in their role as messengers. IL-2, 
released by these cells, is responsible for the activation and differentiation of 
T cell and natural killer cells (NK) cells (spontaneous cytotoxic), to induce the 
cytotoxicity of CD8 + T lymphocytes and to promote activation and 
proliferation of B lymphocytes, hence these cells are considered a 
fundamental pillar in the cell-mediated immune response [9].
Thus, CD4 + T lymphocytes, CD8 + T lymphocytes, macrophages, 
neutrophils, eosinophils, NK cells and the activation of antibody-dependent 
cellular cytotoxicity (ADCC) are immune effector mechanisms to kill cells 
infected by viruses, neoplastic cells or eliminate bacteria and 
parasites_[9,10].
Another interesting aspect of ozone as an immunomodulator is during the 
controlled "micro-oxidation" that occurs after administration, the "vaccine 
effect”, which gives a favorable activation of antioxidant systems [11].
Given the widely recognized immune stimulatory effect of ozone therapy, the 
aim of this study is to determine the effectiveness of increased doses of 
major autohemotherapy on the humoral, immunological and biochemical 
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Materials and methods 
A retrospective longitudinal study was performed at the Cardiozono Medical 
Center located in Luanda, Angola. Twenty-eight adult patients of both sexes, 
who started treatment at the Medical Center in June 2016 until June 2017, 
were referred from our Gastroenterology office / Infectology consult and 
other Hospitals, diagnosed of chronic hepatitis B of one year of evolution.
Inclusion criteria: Patients with surface antigen (HBs) positive, antibodies 
against surface antigen (Anti-HBs) negative, viral load (HVB DNA) and 
Glutamic Pyruvic Transaminase (TGP), as well as Glutamic Oxaloacetic 
Transaminase (TGO) elevated with retroviral treatment in 1 year of evolution.
Exclusion criteria: Pregnant women, patients with other chronic diseases, 
autoimmune diseases, degenerative diseases, as well as patients with 
coagulation disorder 
Treatment Protocol: The patients received 15 sessions of major 
autohemotherapy (one daily session). In each session we used a German-
made Promedic Humazon equipment (Humares GmbH, Bruchsal, 
Germany), 3-way stopcock, epicranial needle 19 G, Sangiset (Humares 
GmbH, Bruchsal, Germany) with capacity of 350 mL where we put 10 mL of 
3.13 % sodium citrate to avoid blood clot during the procedure and other 
disposable material.
The major autohemotherapy (Table 1) was performed at a concentration of 
50 μg/mL in 100 m of blood; the initial dose of the therapy was 4000 μg (80 
mL of ozone gas at 50 μg/mL concentration); we increased the dose by 2000 
μg every 2 days until reaching a dose of 12,000 μg (240 mL of ozone gas at 
50 μg/mL concentration), maintaining this dose as a maintenance dose 
every 15 days throughout the year. 
The parameters evaluated were: Ag HBs, Anti-HBs, HVB viral load and 
transaminases, before starting the treatment, at 15 days of completion, at 6 
months and 1 year.
We considered the qualitative result of the serological markers Ag HBs, Anti-
HBs (positive/negative).
The real-time PCR reference values were taken into account as a 
standardized method to determine the Viral Load with an analytical range of 
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Table 1. Treatment protocol.
        Days of treatment O3 dose in 100 ml of blood 
(O3 concentration and volume)
Days 1-2 4,000 µg (50 µg/mL and 80 ml)
Days 3-4 6,000 µg (50 µg/mL and 120 ml)
Days 5-6 8,000 µg (50 µg/mL and 160 ml)
Days 7-8 10,000 µg (50 µg/mL and 200 ml)
Days 9-15 12,000 µg (50 µg/mL and 240 ml)
Maintenance every 15 days 12,000 µg (50 µg/mL and 240 ml)
JO3TJavier Cespedes-Suarez 
The values of biochemical markers (TGP) and (TGO) less than or equal to 
40 ID/L were taken into account according to the reference values of the 
laboratory where the tests were performed.
Statistical analysis: We used SPSS 19.0 statistic software and we 
categorized the values using contingency tables utility and chi-square 
analysis for the significance on the changes before and after the treatment. 
Values of chi-square under 0,05 were considered significant.

Results and discussion 
The anti-hepatitis B surface antigen (Ag HBs), formerly known as "Australian 
antigen" is the most important serological marker, appears in the serum 1 to 
10 weeks after acute exposure to HBV, before the onset of symptoms or 
elevation of aminotransferases. Its persistence for more than 6 months 
implies chronic infection and its loss is a desirable objective followed by the 
appearance of Anti-HBs in the majority of patients [12].

Of the 28 patients with a positive HBsAg serological marker before starting 
treatment, 100% were negativized per month, maintaining these results at 6 
months and a year in the total sample (Table 2). This process suggests that 
the immune response to autohemotherapy was favorable, although it is 
unable to eradicate the virus, tends to decrease the progression of the 
infection. It has to be considered that, the method used for this marker was 
qualitative and only provides information on the total antibody response to 
Anti-HBs. These results could be related to the use of ozone concentration 
of 50 μg/mL in doses reaching 12,000 μg during the maintenance therapy 
that was able to modulate the release of cytokines, determinant for 
synthesis of these antibodies, coinciding with studies that have already 
demonstrated that high ozone concentrations (50 to 80 μg/mL) are capable 
of modulating the release of these cytokines, as expression of different 
biological functions [13].

The goal of HBV therapy is the suppression of virus replication to prevent 
disease progression; it should be aimed at maintaining the lowest possible 
title of HBV DNA.
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Table 2: Behavior of serological markers (Ag HBs, Anti-HBs) in 28 patients during 




                                   Patients Number
Before starting 
treatment 1 month 6 months 1year
Ag HBs + 28(100%) 0 0 0
Ag HBs - 0 28(100%)* 28(100%)* 28(100%)*
Anti-HBs + 0 28(100%)* 28(100%)* 28(100%)*
Anti-HBs - 28(100%) 0 0 0
*chi-square significant value.
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of the patients (57.1%) presented viral load between 10,000-20,000 IU/mL. 
At one month the viral load was undetectable in 100% of the patients, 
maintaining this level during the year under treatment (Table 3). The results 
obtained can be compared with similar previous work reported by Jiao XJ et 
al in 2008 and Neronov in 2009 [14,15].

It is necessary to point out that, 15 days after the conclusion of ozone cycle 
by major autohemotherapy, a good response of the immune system was 
observed, maintained in a sustained way. This could be explained by the 
cumulative effects of the active metabolites produced during the ozone 
therapy that stimulates different pathways which ultimately result in an 
immune stimulation.

Ozone is considered by several authors as a drug capable of modifying the 
biological response by the multiplicity of action and the generation of 
intermolecular signalizations [14,15,16].

The transaminases or aminotransferases are enzymes present inside the 
cells of our body, being responsible for the metabolism of some proteins. 
They are present in several body cells and  in great quantity in the 
hepatocytes (liver cells). Whenever a cell that contains TGO or TGP suffers 
an injury, these enzymes "pour" into the blood, increasing their blood 
concentration. Therefore, it is easy to understand why liver diseases, which 
cause hepatocyte injury, occur with elevated blood levels of them, as may 
occur in the course of hepatitis.
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Table 3: Viral load behavior in 28 patients with ozone by major autohemotherapy 
during one year of treatment.





1 month 6 months 1year
Undetectable 0(0%) 28(100%)* 28(100%)* 28(100%)*
40 - 10,000 12(29.6%) 0 0 0
10,000 - 20,000 16(57.1%) 0 0 0
*chi-square significant value.
Table 4: Behavior of different biochemical markers in 28 patients treated with ozone 




TGO and TGP 
(IU/L)
Before starting 
treatment 1 month 6 months 1year
< 40 0 28 (100%)* 28(100%)* 28(100%)*
40-100 28 (100%) 0 0 0
*chi-square significant value.
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Before initiating treatment, 100% of the patients had elevated transaminase 
levels (TGP and TGO) between 40-100 IU/L. At one month, 100% of the 
sample had normal values (< 40 Uds/L), remaining at 6 months and one 
year of treatment, which is closely related to the decrease in viral load 




Ozone therapy by major autohemotherapy has a stimulatory effect on the 
humoral response to the surface antigen of the Hepatitis B virus, as well as 
on the biochemical markers. The evaluation of the viral load, at different 
times of the therapy, was a marker of effectiveness to evaluate the 
persistence of the organism positive response to the ozone treatment by 
major autohemotherapy.  No side effects were found during the study.
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